Japan’s highest court for intellectual property disputes has dismissed Shionogi’s (TYO: 4507) lawsuit against a decision by the board of the Japanese Patent Office, related to the firm’s Japanese patent for HIV integrase inhibitors.
The case relates to a filing from Shionogi against MSD, the ex-North American name for USA’s Merck & Co (NYSE: MRK), stating that MSD’s integrase inhibitor Isentress (raltegravir) infringes the patent.
The Patent Office invalidated that patent in August 2017, following a legal action from MSD, a decision which Shionogi filed to have revoked.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze